Cancer Clinical Trials: Implications for Oncology Nurses

被引:5
|
作者
Portier, Wendy S. [1 ]
机构
[1] Portier & Associates LLC, New Orleans, LA USA
关键词
clinical trial; Food and Drug Administration; biomarker; informed consent; protocol; adverse event; clinical trial navigator;
D O I
10.1016/j.soncn.2020.150998
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To explore the various types and phases of clinical trials, the regulatory oversight, drug approval process, and implications of clinical trials for the oncology nurse. Data Sources: Peer-reviewed journal articles, internet, book chapters, white papers. Conclusion: Oncology nurses' interactions with patients entered on clinical trial and communication with the clinical research team is crucial to the successful conduct of clinical trials. The oncology nurse must work in concert with the clinical research team to protect patient safety and to produce accurate information for protocol requirements that will be used to evaluate whether a drug becomes approved or not by the US Food and Drug Administration. Implications for Nursing Practice: Oncology nurses play a central role to the successful outcome of clinical research studies. Nurses must work in close collaboration with the clinical research teams for the successful completion and adherence of the clinical trial and to maintain the safety of the patient enrolled into clinical trial. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页数:6
相关论文
共 50 条
  • [11] Improving attribution of adverse events in oncology clinical trials
    George, Goldy C.
    Barata, Pedro C.
    Campbell, Alicyn
    Chen, Alice
    Cortes, Jorge E.
    Hyman, David M.
    Jones, Lee
    Karagiannis, Thomas
    Klaar, Sigrid
    Le-Rademacher, Jennifer G.
    LoRusso, Patricia
    Mandrekar, Sumithra J.
    Merino, Diana M.
    Minasian, Lori M.
    Mitchell, Sandra A.
    Montez, Sandra
    O'Connor, Daniel J.
    Pettit, Syril
    Silk, Elaine
    Sloan, Jeff A.
    Stewart, Mark
    Takimoto, Chris H.
    Wong, Gilbert Y.
    Yap, Timothy A.
    Cleeland, Charles S.
    Hong, David S.
    CANCER TREATMENT REVIEWS, 2019, 76 : 33 - 40
  • [12] Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602)
    Freedman, Rachel A.
    Dockter, Travis J.
    Lafky, Jacqueline M.
    Hurria, Arti
    Muss, Hyman J.
    Cohen, Harvey J.
    Jatoi, Aminah
    Kemeny, M. Margaret
    Ruddy, Kathryn J.
    ONCOLOGIST, 2018, 23 (09) : 1016 - 1023
  • [13] Key clinical trials in gynaecological oncology
    Morrison, J.
    Kehoe, S.
    EJSO, 2006, 32 (08): : 887 - 891
  • [14] Funding and Sponsorship of Clinical Trials in Oncology
    Bruns, Johannes
    ONKOLOGIE, 2010, 33 : 16 - 18
  • [15] Approaches for Discussing Clinical Trials with Pediatric Oncology Patients and Their Families
    Blazin, Lindsay J.
    Cuviello, Andrea
    Spraker-Perlman, Holly
    Kaye, Erica C.
    CURRENT ONCOLOGY REPORTS, 2022, 24 (06) : 723 - 732
  • [16] Approaches for Discussing Clinical Trials with Pediatric Oncology Patients and Their Families
    Lindsay J. Blazin
    Andrea Cuviello
    Holly Spraker-Perlman
    Erica C. Kaye
    Current Oncology Reports, 2022, 24 : 723 - 732
  • [17] Exploring consent to randomized placebo-controlled clinical trials in oncology
    Tolerton, Sarah K.
    Shaw, Joanne
    O'Reilly, Amanda
    Dunn, Stewart
    Boyle, Frances M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (03) : 300 - 306
  • [18] Methodological quality of oncology noninferiority clinical trials
    Wayant, Cole
    Ross, Andrew
    Vassar, Matt
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 149
  • [19] Clinical trials in oncology:: specific methodology problems
    Baumelou, E
    Méry-Mignard, D
    Lehner, JP
    THERAPIE, 2002, 57 (04): : 358 - 365
  • [20] New designs for basket clinical trials in oncology
    Simon, Richard
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2018, 28 (02) : 245 - 255